Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04395911 · ClinicalTrials.gov registry record · NA
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
A NA study, sponsored by SeaStar Medical.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT04395911: Completed NA study, sponsored by SeaStar Medical.
NCT04395911 is a NA study that has completed, run by SeaStar Medical. The registered enrollment target is 22 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04395911, a NA study, has completed, sponsored by SeaStar Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
Selective Cytopheretic Device (SCD) treatments will improve survival in patients testing positive for COVID-19 infection diagnosed with Acute Kidney Injury (AKI) or ARDS.
Primary Outcome
All cause mortality at Day 60
Interventions
- DEVICE SCD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2020-09-10 |
| Est. Completion | 2021-07-21 |
| Phase | NA |
What the finished NCT04395911 record still lists
NCT04395911 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which SCD is the first listed.
NCT04395911 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04395911 about?
NCT04395911 is a clinical study titled "Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections". Selective Cytopheretic Device (SCD) treatments will improve survival in patients testing positive for COVID-19 infection diagnosed with Acute Kidney Injury (AKI) or ARDS.
What is the current status of trial NCT04395911?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2020-09-10. Estimated completion is 2021-07-21.
What interventions are being tested in trial NCT04395911?
The interventions under investigation include: SCD (DEVICE).
Who is sponsoring clinical trial NCT04395911?
This trial is sponsored by SeaStar Medical, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04395911's enrollment target sits among peer trials
22 1756th of 2000 higher than 239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI